Siemens Healthineers invests $30M into new radiopharmaceutical facility
Siemens Healthineers on Wednesday announced its plans to invest tens of millions of dollars into a new radiopharmaceutical manufacturing site in the United Kingdom.
Located in Dunstable, England, the site will have up to eight times the manufacturing capacity of any other radiopharmaceutical facility. The new facility, which will reportedly cost around the equivalent of $30 million USD, is being developed to provide the region with a more reliable supply chain of radiopharmaceuticals.
It will come complete with two high-energy cyclotrons, multiple clean rooms and hot cells, purpose‑built dispatch areas and a vast quality control laboratory. All critical equipment will come equipped with dual backups to ensure operational resilience.
The Dunstable site’s location will play a key role in stabilizing the supply chain in the area, enabling same-day delivery for a slew of PET/CT centers across the region. This will expand access to critical diagnostics and treatments that might not have been previously available to patients in the area.
“The radiopharmaceutical market is accelerating, and supply must not become the limiting factor. That is why we are investing in an 8X radiopharmacy here in the UK, the first facility of its kind, designed to deliver eight times the production capacity of one of our conventional radiopharmacies,” Ghada Trotabas, managing director of Siemens Healthineers Great Britain and Ireland, said in a statement. “This is not just about scale. It is about resilience, reliability, and long-term certainty of supply. Above all, it is about giving the NHS, and the patients it serves, the confidence that access to critical diagnostics will keep pace with growing clinical demand, today and into the future.”
Josh Nutting, managing director, Radiopharma International at Siemens Healthineers, added that the new facility “represents a significant milestone.”
“With the 8X facility in Dunstable, we are making a long‑term commitment to the UK market—strengthening our ability to supply high‑quality radiopharmaceuticals reliably and at scale, while preparing for the next wave of diagnostic and therapeutic innovation,” Nutting said.
Read more here.
In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.